Reuters logo
8 months ago
BRIEF-Gamida Cell informs Elbit that FDA clears Gamida Cell to begin Phase 3 Nicord study enrolment
December 12, 2016 / 5:35 PM / 8 months ago

BRIEF-Gamida Cell informs Elbit that FDA clears Gamida Cell to begin Phase 3 Nicord study enrolment

Dec 12 (Reuters) - Elbit Imaging Ltd :

* Gamida Cell informed Co that Gamida Cell has been cleared by FDA to begin enrolling for Phase 3 study of Nicord

* A total of 120 patients will be enrolled at transplantation centers throughout U.S. and Europe for Nicord Phase 3 study

* Gamida Cell has informed Co clearance to begin enrolling for Nicord study has also been received for additional European territory

* Gamida Cell estimates that patient recruitment will take approximately two years to complete Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below